Loading...
XSTOABLI
Market cap64mUSD
Dec 23, Last price  
0.42SEK
1D
0.36%
1Q
137.85%
Jan 2017
-84.38%
IPO
-87.34%
Name

Abliva AB

Chart & Performance

D1W1MN
XSTO:ABLI chart
P/E
—
P/S
5,219.15
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
67.36%
Rev. gr., 5y
93.89%
Revenues
137k
+341.94%
0908,6604,432,6733,452,7675,556,0001,113,0005,335,0007,152,0002,502,00014,00027,0005,000134,000216,000151,00031,000137,000
Net income
-96m
L+12.41%
-1,227,131-1,557,575-1,528,500-4,773,642-9,386,000-14,873,000-22,331,000-42,549,000-90,119,000-70,240,000-66,728,000-68,373,000-76,874,000-59,883,000-123,498,000-84,964,000-95,509,000
CFO
-8m
L-95.11%
-997,923-2,224,735-637,780-5,011,602-8,588,000-12,222,000-19,090,000-43,632,000-67,220,000-57,377,000-58,124,000-63,829,000-72,412,000-67,558,000-114,075,000-159,560,000-7,802,000
Earnings
Feb 21, 2025

Profile

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
URL
https://abliva.com/
IPO date
Oct 03, 2008
Employees
8
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
137
341.94%
31
-79.47%
151
-30.09%
Cost of revenue
122,457
143,820
123,199
Unusual Expense (Income)
NOPBT
(122,320)
(143,789)
(123,048)
NOPBT Margin
Operating Taxes
(9)
(300)
4
Tax Rate
NOPAT
(122,311)
(143,489)
(123,052)
Net income
(95,509)
12.41%
(84,964)
-31.20%
(123,498)
106.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
752
180,364
75,868
BB yield
Debt
Debt current
Long-term debt
848
1,403
Deferred revenue
Other long-term liabilities
1,000
Net debt
(69,917)
(78,090)
(35,440)
Cash flow
Cash from operating activities
(7,802)
(159,560)
(114,075)
CAPEX
(1,290)
(905)
(1,089)
Cash from investing activities
(1,290)
(905)
(1,089)
Cash from financing activities
414
204,417
75,792
FCF
(57,767)
(208,754)
(122,728)
Balance
Cash
57,664
66,392
22,339
Long term investments
13,101
13,101
13,101
Excess cash
70,758
79,491
35,432
Stockholders' equity
(835,254)
(740,934)
(689,032)
Invested Capital
906,396
905,756
730,560
ROIC
ROCE
EV
Common stock shares outstanding
1,056,299
739,487
379,365
Price
Market cap
EV
EBITDA
(120,486)
(141,179)
(120,388)
EV/EBITDA
Interest
76
2,764
12
Interest/NOPBT